Details:
Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
Lead Product(s): KYN-5356
Therapeutic Area: Neurology Product Name: KYN-5356
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $62.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 07, 2023
Details:
AMT-240 is a one-time-administered gene therapy using uniQure’s miQURE gene-silencing technology to silence the toxic APOE variant, in combination with overexpressing a protective APOE variant as treatment for autosomal dominant Alzheimer’s disease patients.
Lead Product(s): AMT‑240
Therapeutic Area: Neurology Product Name: AMT‑240
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules. In a mouse model, this reduces poly-GA aggregates and largely prevents motor deficits.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: European Union
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 06, 2022
Details:
The new data demonstrate therapeutic potential and versatility of VectorY’s VecTab platform technology, enabling development of secreted or intracellular antibody fragments that are AAV-VecTabs delivered to neurons and/or astrocytes, in vitro and in vivo.
Lead Product(s): AAV-VecTabs
Therapeutic Area: Neurology Product Name: AAV-VecTabs
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
VTx-002, reduce TDP-43 pathological aggregates for treating ALS, TAR-DNA binding protein-43 is necessary for correct processing and transport of multiple mRNA’s that are essential for neuronal survival.
Lead Product(s): VTx-002
Therapeutic Area: Neurology Product Name: VTx-002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
AMT-210 (miRNA-based AAV Gene Therapy) is a one-time, brain-targeting AAV gene therapy incorporating miQURE gene silencing technology, designed to halt misfolded alpha-synuclein and subsequent fibril formation in familial and sporadic Parkinson’s disease patients.
Lead Product(s): miRNA-based AAV Gene Therapy
Therapeutic Area: Neurology Product Name: AMT-210
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team.
Lead Product(s): Vectorized Antibodies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $36.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021